Drugs / 64Cu-SARTATE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04440956 | May 2015 → Feb 2016 | neuroendocrine neoplasm | Clarity Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03936426 | Jul 2018 → Sep 2019 | meningioma | Clarity Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04438304 | Mar 2021 → Nov 2024 | digestive system neuroendocrine neoplasm | Clarity Pharmaceuticals Ltd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04023331 Background | Aug 2020 → Jan 2025 | neuroblastoma | Clarity Pharmaceuticals Ltd | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 64Cu-SARTATE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04440956 ↗ |
| Known as | Cu-64 SARTATE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03936426 ↗ |
| Modality | Peptide | “attached to the somatostatin analog octreotate using the sarcophagine MeCOSar chelator (SARTATE)” PMID 36460344 ↗ Dec 2022 |
| Route | Intravenous | “200 MBq of Cu-64 SARTATE given as a single bolus intravenous injection” NCT03936426 ↗ |